Media coverage about Orthofix International (NASDAQ:OFIX) has trended somewhat positive on Sunday, Accern reports. Accern rates the sentiment of media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Orthofix International earned a coverage optimism score of 0.22 on Accern’s scale. Accern also assigned headlines about the medical device company an impact score of 44.8195946973533 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
Shares of Orthofix International (NASDAQ:OFIX) traded up $1.40 on Friday, hitting $55.00. The company had a trading volume of 267,746 shares, compared to its average volume of 116,978. Orthofix International has a 52-week low of $33.90 and a 52-week high of $56.53. The stock has a market capitalization of $1,002.71, a PE ratio of 785.83, a price-to-earnings-growth ratio of 2.39 and a beta of 0.14.
Orthofix International (NASDAQ:OFIX) last issued its quarterly earnings results on Monday, October 30th. The medical device company reported $0.42 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.41 by $0.01. Orthofix International had a return on equity of 10.26% and a net margin of 0.33%. The firm had revenue of $105.30 million during the quarter, compared to analysts’ expectations of $100.67 million. During the same period in the previous year, the business earned $0.36 earnings per share. The firm’s revenue for the quarter was up 6.9% on a year-over-year basis. equities analysts predict that Orthofix International will post 1.61 EPS for the current fiscal year.
In other Orthofix International news, Director Luke T. Faulstick sold 4,800 shares of the company’s stock in a transaction on Monday, November 6th. The stock was sold at an average price of $51.22, for a total value of $245,856.00. Following the completion of the sale, the director now directly owns 7,729 shares in the company, valued at approximately $395,879.38. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Brad Mason sold 5,000 shares of the company’s stock in a transaction on Tuesday, November 28th. The shares were sold at an average price of $53.48, for a total value of $267,400.00. Following the completion of the sale, the chief executive officer now owns 183,053 shares of the company’s stock, valued at $9,789,674.44. The disclosure for this sale can be found here. Insiders have sold 15,347 shares of company stock valued at $802,144 over the last quarter. 5.60% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: This story was published by Ticker Report and is the sole property of of Ticker Report. If you are viewing this story on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark laws. The original version of this story can be accessed at https://www.tickerreport.com/banking-finance/3148958/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-orthofix-international-ofix-stock-price.html.
Orthofix International Company Profile
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
Receive News & Ratings for Orthofix International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International and related companies with MarketBeat.com's FREE daily email newsletter.